S-3 ·Filed May 7, 2026

KALA

KALA BIO, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001829126-26-004790
Shelf registration — potential dilution
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplement that would detail an actual debt issuance, pricing, and use of proceeds. Until then, this filing is a routine capital markets step with no immediate trading implications.

DirectionNeutral
Confidencemedium
Horizonmonths
Final — all horizons settled through T+60d
KALA ▼ -81.19% at T+60d
NEUTRAL call ✗ call lost -81.19% · α vs SPY -86.03% · entry $3.95 → $0.7430
Entry anchored
May 7, 2026
via day open
T+1d
-1.01%
call -1.01% · α -1.24%
$3.91
settled 5mo ago
T+5d
-21.77%
call -21.77% · α -23.24%
$3.09
settled 5mo ago
T+20d
-47.85%
call -47.85% · α -47.87%
$2.06
settled 4mo ago
T+60d
-81.19%
call -81.19% · α -86.03%
$0.7430
settled 8w ago

Price Chart

Loading chart...

Executive Summary

KALA BIO filed an S-3 shelf registration to issue an unlimited amount of senior and subordinated debt securities. The filing is a standard capital markets preparation and does not include any specific offering terms or amounts. As a routine shelf registration with no immediate pricing, the impact is minimal and neutral.

Key Facts

  • Filed S-3 shelf registration for an unlimited aggregate principal amount of debt securities.
  • Includes indentures for both senior and subordinated debt, but no specific terms or amounts are disclosed.
  • No immediate offering or pricing details provided; the filing is preparatory in nature.

Financial Impact

No specific dollar amounts disclosed.

Risk Factors

  • Potential future debt issuance could dilute equity or increase leverage.
  • No specific financial data in the filing to assess need for capital.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001829126-26-004790
Document: kalabio_ex4-5.htm0001829126-26-004790
5 reports for KALA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +77.78%Jun 26, 2026
Filters
Rows
Reports for KALA — sortable, filterable
TypeNow
Aug 28, 2026
5w ago
8-K
BEARISH ★ 8/10
$0.6901 $0.4502▲ +34.76%▲ +35.02%$0.3884 (+43.72%)
Jul 22, 2026
10w ago
424B5
BEARISH ★ 8/10
$0.6103 $0.8401▼ −37.65%▼ −34.35%$0.3884 (+36.36%)
Jun 26, 2026
14w ago
EFFECT
BEARISH ★ 7/10
$2.52 $0.6103▲ +75.78%▲ +77.04%$0.3884 (+84.59%)
May 7, 2026
21w ago
S-3
NEUTRAL ★ 2/10
$3.95 $2.06▼ −47.85%▼ −47.87%$0.3884 (−90.17%)
Mar 4, 2026
30w ago
Press Release
MIXED ★ 6/10
$17.25 $0.1630▼ −99.06%▼ −94.64%$0.3884 (−97.75%)
Showing 5 of 5

US Market Status

Market Open — Closes in 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access